Respiratory Syncytial Virus : The race to market continues

The first wave of Ipsos’s Syndicated Global RSV study, fielded in 8 markets in Europe.

Ipsos | RSV The race to market Following on from our November 2022 article, RSV: On The Verge of Change, in this short editorial we outline the current RSV landscape status, as several companies remain key contenders to launch the first vaccine.

Ipsos’ syndicated data is used to highlight key considerations affecting both physicians and consumers.

Download the full paper

Download

The author(s)

More insights about Health

Related news

  • KEYS: Our World in Motion
    E mobility Webinar

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?